Two new pivotal Chinese first-line trials have started in lung cancer.
ApexOnco Front Page
Recent articles
AZD0120’s first pivotal trial will test settings as early as the second line.
Data in the coming months will inform which immunotherapy the UK company takes into pivotal development.
Meanwhile, Torl BioTherapeutics appears to be catching up with BioNTech.
HanchorBio’s HCB301 is among the latest industry projects beginning first-in-human trials.
Two years after being snubbed by GSK, Ideaya shows the promise of MAT2A inhibition.
The implosion of Skyscraper-06 has a direct impact on at least two other TIGIT players.
The group abandons plans in lung cancer with Met exon 14 skipping, to focus on Met amplifications.